. . . . . . . . . "clinical trial"@en-ca . . . . . . . . . . . . "ensayo cl\u00EDnico"@es . . "18"^^ . "essai clinique"@fr . . . . . . . . . . . . . . "2018-10-31T00:00:00Z"^^ . . . . . . . . . . . . . . . "213"^^ . . . . . . . . . "NCT02775903" . . . . . "2016-06-03T00:00:00Z"^^ . . "clinical trial"@en . . . . "clinical trial"@en-us . . "\u056F\u056C\u056B\u0576\u056B\u056F\u0561\u056F\u0561\u0576 \u0583\u0578\u0580\u0571\u0561\u0580\u056F\u0578\u0582\u0574"@hy . . . . . "ensaio cl\u00EDnico"@gl . . . . . . . "klinisch onderzoek"@nl . . "assaig cl\u00EDnic"@ca . . . . . . . . "An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)"@en . . . . . . . "ensayu cl\u00EDnicu"@ast . . "clinical trial"@en-gb . "A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)"@en . "An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)"@en . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . "An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)"@en . . . . .